期刊
TRANSPLANT INTERNATIONAL
卷 36, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/ti.2023.10704
关键词
lung transplantation; everolimus; calcineurin inhibitor; lung transplant recipients; mammalian-target-of-rapamycin inhibitor; lung transplant survival; nephrotoxicity
Everolimus (EVE) is an alternative immunosuppressive agent for lung transplant recipients (LTR) who cannot tolerate conventional immunosuppression. It can be used as part of a calcineurin inhibitor (CNI) minimization or elimination strategy. This study compared the safety and efficacy outcomes of EVE in LTR receiving either a CNI minimization or elimination regimen. The results showed that LTR receiving EVE as part of the CNI elimination strategy had poorer survival outcomes, while the utilization of EVE for renal preservation was associated with improved survival. The study highlighted the importance of retaining a low dose CNI in immunosuppressive regimens for superior survival outcomes.
Everolimus (EVE) provides an alternative to maintenance immunosuppression when conventional immunosuppression cannot be tolerated. EVE can be utilized with a calcineurin inhibitor (CNI) minimization or elimination strategy. To date, clinical studies investigating EVE after lung transplant (LTx) have primarily focused on the minimization strategy to preserve renal function. The primary aim was to determine the preferred method of EVE utilization for lung transplant recipients (LTR). To undertake this aim, we compared the safety and efficacy outcomes of EVE as part of minimization and elimination immunosuppressant regimens. Single center retrospective study of 217 LTR initiated on EVE (120 CNI minimization and 97 CNI elimination). Survival outcomes were calculated from the date of EVE commencement. On multivariate analysis, LTR who received EVE as part of the CNI elimination strategy had poorer survival outcomes compared to the CNI minimization strategy [HR 1.61, 95% CI: 1.11-2.32, p=0.010]. Utilization of EVE for renal preservation was associated with improved survival compared to other indications [HR 0.64, 95% CI: 0.42-0.97, p=0.032]. EVE can be successfully utilized for maintenance immunosuppression post LTx, particularly for renal preservation. However, immunosuppressive regimens containing low dose CNI had superior survival outcomes, highlighting the importance of retaining a CNI wherever possible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据